Showing recent highlights
What's New
PubMed (Open Access Guidelines) · December 1, 2026
A study looked at data from over 17,000 people with early-stage breast cancer to compare different chemotherapy combinations and schedules. Researchers found that certain combinations and timing of chemotherapy drugs — specifically giving some drugs together versus one after another — appeared to work better at helping people stay cancer-free and live longer. People with early-stage breast cancer may want to ask their doctor how the timing and combination of their chemotherapy plan compares to the latest research findings.
What's New
PubMed · June 4, 2026
Researchers found that in people with a type of breast cancer called triple-negative breast cancer, having detectable tumor DNA circulating in the blood after chemotherapy treatment (given before surgery) was linked to a significantly higher chance of the cancer coming back. Specifically, patients with this detectable tumor DNA were more than four times more likely to have a recurrence than those without it, which could eventually help doctors identify who might need closer monitoring or additional treatment after surgery. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed (Guideline Reviews) · June 4, 2026
The text does not clearly name a medical society or authoritative body issuing formal recommendations, so it cannot be treated as a clinical guideline. It is instead a review and proposal from researchers at the International Hereditary Cancer Center in Szczecin, suggesting that Polish guidelines be updated to offer preventive breast removal surgery to more women with certain inherited gene variants — specifically those carrying changes in the TP53, PTEN, PALB2, or CHEK2 genes — because these variants raise the risk of developing breast cancer. If people with breast cancer or a strong family history of it have questions about genetic testing or their options, speaking with their doctor would be the best next step.
Ask your doctor: Ask the doctor whether the patient has been tested for genetic mutations like TP53, PTEN, PALB2, or CHEK2 that might affect whether prophylactic mastectomy should be considered.
What's New
PubMed · June 1, 2026
Researchers found that some people with a type of breast cancer called HER2-positive early breast cancer — meaning the cancer cells have a protein called HER2 that makes them grow faster — may be able to skip chemotherapy entirely and still do well. In the study, patients were treated with targeted medicines (trastuzumab and pertuzumab, which are drugs that directly attack the HER2 protein) before surgery, and those whose cancer completely disappeared by the time of surgery continued without chemotherapy afterward. This suggests that for certain patients, it may be possible to avoid the harsh side effects of chemotherapy while still effectively treating the cancer — though this is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that for women who have a mastectomy (surgery to remove the breast), the timing of reconstruction surgery may matter depending on the type of reconstruction used. When reconstruction uses an implant, having it done immediately during the same surgery as the mastectomy was linked to roughly twice the rate of complications compared to waiting and doing it later — but when reconstruction uses the patient's own tissue (taken from another part of the body), the timing didn't seem to make a meaningful difference in complication rates. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that a focused, high-dose form of radiation therapy — delivered in just five treatment sessions — appeared to be safe and well-tolerated in a small group of elderly breast cancer patients (average age 91) who couldn't have or didn't want surgery. No serious side effects were seen across any of the three dose levels tested, which is an encouraging early sign for people who may not have many other local treatment options. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
A study found that for postmenopausal people with early breast cancer, receiving a single infusion of a bone-strengthening drug called zoledronate worked about as well as getting an infusion every six months for three years — with similar rates of cancer coming back, cancer spreading to the bones, and survival after five years. Zoledronate is a medication given through an IV that helps protect bones and may reduce the risk of cancer spreading there. This appears to be a new finding about dosing convenience, suggesting a simpler, one-time treatment approach may be a reasonable option compared to the more frequent schedule.
Ask your doctor: Ask the doctor whether the patient might be a good candidate for a single zoledronate infusion instead of getting infusions every 6 months, since studies show the single dose works about as well but is easier to tolerate.
Guidelines
PubMed (Guideline Reviews) · June 1, 2026
According to Society of Surgical Oncology guidelines, women aged 70 or older with early-stage breast cancer that is hormone receptor-positive and HER2-negative — meaning the cancer is driven by hormones rather than a specific protein — may not need a sentinel lymph node biopsy (a procedure to check nearby lymph nodes for cancer spread) if their lymph nodes appear normal and they are receiving hormone-blocking treatment. The guidelines suggest skipping this procedure in carefully selected patients is safe, because studies show it does not meaningfully increase the chances of cancer returning or affect survival. Despite this recommendation, many eligible women are still receiving the procedure, which means some patients may be undergoing surgery they don't need — making it worth discussing with their doctor whether it applies to their situation.
What's New
PubMed · June 1, 2026
Researchers found that two types of cooling treatments — a scalp cooling device and a chemical cooling cap worn during chemotherapy — were both effective at helping people with early breast cancer keep most of their hair, with success rates of about 74% and 71% respectively. The chemical cooling cap group, however, reported feeling less anxious and having a better overall quality of life during treatment. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
A study found that for Chinese American breast cancer survivors, a type of journaling called expressive writing — where people write about their emotions and how they cope — seemed to improve quality of life, but mainly for those with higher incomes (above $15,000 per year). Researchers also noticed early hints that being unmarried may have influenced how much benefit people got from certain styles of writing. This matters because it suggests that a person's life circumstances, like their financial situation, may shape how well emotional support programs work for them. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that for people with a common type of breast cancer driven by hormones (called hormone receptor-positive), adding immunotherapy — a treatment that helps the immune system fight cancer — did not broadly improve how well treatment worked overall, but it did increase the chances of the cancer fully disappearing (called a complete response). However, immunotherapy was also linked to a higher chance of treatment-related side effects. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that a surgical technique called targeted axillary dissection — where a suspicious lymph node near the breast is marked and then removed to check for cancer spread — showed promising accuracy in a small group of breast cancer patients who had surgery without chemotherapy first. The marking method mattered a lot: some types of markers were harder to locate during surgery than others, and in about a third of cases, cancer was found in nearby lymph nodes that weren't part of the targeted removal, suggesting the technique might miss some spread. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
A study found that people having breast cancer surgery who received targeted nerve-blocking injections (called regional anesthesia) along with a mild sedative felt noticeably better in the hours after their operation compared to those who received full general anesthesia — meaning they were put completely to sleep. Patients who had the nerve blocks reported less pain and higher overall recovery scores at 2, 6, and 24 hours after surgery. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that certain compounds found in Traditional Chinese Medicine (TCM) — including plant-based ingredients like Wogonin and Resveratrol — may work against breast cancer by targeting multiple biological pathways at once, meaning they appear to interfere with several of the processes cancer cells use to grow and spread. The review also found evidence that TCM may help reduce some of the harsh side effects that can come with standard treatments like chemotherapy and radiation. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
A study found that in people with a specific type of breast cancer called triple-negative breast cancer — meaning the tumor lacks three common markers that doctors test for — certain proteins in the tumor may help predict which chemotherapy approach works best. Researchers found that the presence or absence of proteins called EZH2 and TUBB in the tumor appeared to influence whether patients did better with one chemotherapy combination versus another. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
A study found that for people diagnosed with low-grade ductal carcinoma in situ (DCIS) — a very early, slow-growing form of abnormal cells in the breast — closely watching the condition over time instead of rushing to surgery (called "active surveillance") is a real option being explored, but how people feel about it varies a lot based on worry, trust in their doctor, and how the information is explained to them. Researchers found that doctors also have concerns, including uncertainty about how the condition might change over time and a lack of clear guidelines for monitoring patients safely. This means people with low-grade DCIS may want to ask their doctor about all available options and what "watching and waiting" would actually look like in their specific situation.
Ask your doctor: Ask the doctor whether active surveillance—where the patient is closely monitored instead of having surgery right away—might be an option for the patient's low-grade DCIS, and what the risks and benefits would be compared to surgery.
Medications
PubMed · June 1, 2026
A study found that a targeted treatment called trastuzumab deruxtecan (brand name Enhertu) helped people with a specific type of advanced breast cancer live longer without their cancer getting worse, compared to standard chemotherapy. This type of breast cancer is called HR-positive, HER2-low or HER2-ultralow — meaning the cancer cells have certain proteins on their surface that this drug is designed to target. Researchers found this benefit held up across different groups of patients, including those whose cancer had stopped responding to earlier hormone-blocking treatments, suggesting this could be a meaningful new option for people in this situation.
Ask your doctor: Ask the doctor whether trastuzumab deruxtecan might work better than standard chemotherapy if the patient's cancer came back after trying an endocrine therapy drug like Ibrance or Kisqali.
What's New
PubMed · June 1, 2026
Researchers found that for people with an advanced form of breast cancer called triple-negative breast cancer — a type that can be harder to treat because it doesn't respond to some common therapies — newer treatments outperformed standard chemotherapy in helping patients live longer and slowing the cancer's spread. In particular, two approaches stood out: a targeted drug called sacituzumab govitecan (which homes in on cancer cells more precisely than traditional chemotherapy) and a combination of chemotherapy with a drug called trilaciclib (which helps protect the body during treatment). This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that for some people with early-stage breast cancer, a specialized PET scan called LymphPET — which looks for cancer spread to the lymph nodes under the arm — might make it possible to skip a surgical procedure called sentinel lymph node biopsy (a small operation to check nearby lymph nodes for cancer). In the study, patients who had a clear scan and skipped that surgery did very well over three years, with nearly no cancer returning in the lymph nodes or spreading to other parts of the body. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that adding the immunotherapy drug pembrolizumab to standard chemotherapy before surgery for an aggressive form of breast cancer called triple-negative breast cancer did not change the type of surgery patients needed or how long recovery took — meaning the extra treatment didn't make surgery more complicated or delay it. This matters because people with this type of breast cancer often worry that adding more treatment could affect their surgical options, and this finding suggests it may not. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that combining a standard lumpectomy (surgery to remove a breast tumor while keeping the breast) with a heat-based treatment called radiofrequency ablation — which uses targeted heat to destroy any remaining cancer cells around the surgical area — may work just as well as traditional radiation therapy in carefully selected breast cancer patients. In the study, the cancer came back in the breast in fewer than 3 out of 100 patients over about four years, and those who skipped radiation reported far less breast pain. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that two different types of radiation treatment for breast cancer that has spread to the brain — one that treats the whole brain and one that targets only the tumors with precise, focused beams — produced very similar survival times and disease progression in patients with a small number of brain tumors. Neither approach was clearly better than the other in terms of how long patients lived or how quickly the cancer progressed. This is early research and hasn't yet changed treatment guidelines.
Lifestyle
PubMed · June 1, 2026
Researchers found that breast cancer survivors who practiced yoga during long-term treatment experienced less fatigue, better sleep, and a higher overall quality of life compared to those who did not. The study, which looked at results from 32 smaller studies involving over 2,400 breast cancer survivors, found that the benefits followed a U-shaped pattern — meaning there was a 'sweet spot' amount of yoga that worked best, with too little or too much being less effective. The researchers were trying to pinpoint exactly how often and how long yoga sessions should be to get the greatest benefit for people going through breast cancer treatment.
What's New
PubMed · June 1, 2026
Researchers found that using immersive virtual reality headsets to experience calming nature scenes — like walking through a virtual forest with soothing music — helped reduce anxiety, distress, and other emotional burdens in people with breast cancer. This kind of technology offers a drug-free way to support mental well-being, which matters because emotional stress is a very common and difficult part of living with breast cancer. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that several mathematical tools — called risk prediction models — exist to help estimate how likely a woman with a family history of breast cancer is to develop the disease, but it's not yet clear which of these tools works best for that group of women. This matters because having a close relative with breast cancer can raise a person's own risk, and a more accurate prediction tool could help doctors have better-informed conversations about monitoring or next steps. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that women taking abemaciclib (a targeted breast cancer drug) along with hormone therapy for early breast cancer commonly experienced diarrhea, with most describing it as their most bothersome side effect — managed through anti-diarrhea medicines and changes to their diet. Despite the discomfort, most women stayed on treatment, partly because they felt the drug gave them a better chance of their cancer not coming back, and they felt supported by their care teams. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that a shorter course of radiation therapy — just 1 week instead of the usual 3 weeks — worked just as well at keeping breast cancer from coming back, even when looking at patients 10 years later. This matters because a shorter treatment schedule could mean less time away from daily life, fewer hospital visits, and potentially fewer side effects for people with early-stage breast cancer. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that a nerve-blocking technique called PECS II — where a doctor injects numbing medication near the chest muscles before breast surgery — may provide longer-lasting pain relief after a full mastectomy compared to a similar technique called an erector spinae block, which targets nerves along the back. People who received the PECS II block also needed fewer extra doses of pain medication in the hours after surgery. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 27, 2026
Researchers found that for people with a type of breast cancer called HR-positive, HER2-negative advanced breast cancer, reusing a class of targeted drugs called CDK4/6 inhibitors — which work by slowing cancer cell growth — after the cancer had already stopped responding to them may still offer some benefit. When these drugs were used again alongside hormone-blocking therapy, patients went an average of 5.8 months before the cancer worsened, compared to 3.7 months with hormone-blocking therapy alone — though no difference in overall survival was seen. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether the patient might benefit from trying a CDK4/6 inhibitor again if the cancer grows after the first CDK4/6 inhibitor treatment stops working.
What's New
PubMed · May 26, 2026
Researchers found that digital health tools — things like apps, online programs, and remote check-ins — may help breast cancer survivors feel less tired, less anxious, and have a better overall quality of life after treatment ends. This matters because many survivors continue to struggle with exhaustion and emotional distress long after their cancer care is finished, and these tools could make support easier to access from home. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.